Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer
Authors
Collection
The Immune System and Cancer\Immunotherapy
The connection between the Immune System and Cancer has been always there, but only recently, it has been possible to uncover some vulnerable targets of the system, check-point inhibitors among others, that look very promising in cancer treatment.This new section will be also open to novel, groundbreaking research manuscripts that deal with aspects of this connection.
We are convinced that this new section will bring an added value to the journal and to our readers. From this page, we encourage scientists and clinicians to submit their manuscripts to the Journal Clinical and Translational Oncology.
We hope that our readers share our enthusiasm of this announcement, the great news of adding a Topical Collection to the Journal.
Articles (103 in this collection)
-
-
Diagnostic impact of 18F-FDG PET/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy
Authors (first, second and last of 6)
-
Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a real-world evidence
Authors (first, second and last of 7)
-
Circulating T regulatory cell subsets in patients with untreated lung cancer
Authors (first, second and last of 7)
-
Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus
Authors (first, second and last of 8)
-
-
Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors
Authors (first, second and last of 6)
-
Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma
Authors (first, second and last of 6)
-
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper
Authors (first, second and last of 11)
-
-
Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer
Authors (first, second and last of 6)
-
PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors
Authors (first, second and last of 6)
-
Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab
Authors (first, second and last of 11)
-
Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer
Authors (first, second and last of 6)
-
The peri- and intratumoral immune cell infiltrate and PD-L1 status in invasive squamous cell carcinomas of the penis
Authors (first, second and last of 7)
-
Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution
Authors (first, second and last of 17)
-
-
A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics
Authors (first, second and last of 6)
-
Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes
Authors (first, second and last of 7)
-
Characterization of a xenograft model for anti-CD19 CAR T cell studies
Authors (first, second and last of 10)
-
Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis
Authors (first, second and last of 12)
-
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel
Authors (first, second and last of 17)
-
Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers
Authors (first, second and last of 5)
-
Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)
Authors (first, second and last of 4)
-
Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression
Authors (first, second and last of 8)
-
A new antisarcoma strategy: multisubtype heat shock protein/peptide immunotherapy combined with PD-L1 immunological checkpoint inhibitors
Authors (first, second and last of 9)
-
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis
Authors (first, second and last of 15)
-
Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial
Authors (first, second and last of 15)
-
PILE: a candidate prognostic score in cancer patients treated with immunotherapy
Authors (first, second and last of 13)
-
Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor
Authors (first, second and last of 14)
-
Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question
Authors (first, second and last of 7)
-
Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus
Authors (first, second and last of 15)
-
Cancer cell-intrinsic STING is associated with CD8 + T-cell infiltration and might serve as a potential immunotherapeutic target in hepatocellular carcinoma
Authors (first, second and last of 10)
-
Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital
Authors (first, second and last of 13)
-
MicroRNA-596 is epigenetically inactivated and suppresses prostatic cancer cell growth and migration via regulating Wnt/β-catenin signaling
Authors (first, second and last of 4)
-
Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy
Authors (first, second and last of 14)
-
The effect of PD-1 expression on tumor-associated macrophage in T cell lymphoma
Authors (first, second and last of 5)
-
The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis
Authors (first, second and last of 4)
-
Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy
Authors (first, second and last of 4)
-
Identification of a novel immune prognostic model in gastric cancer
Authors (first, second and last of 6)
-
Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells
Authors (first, second and last of 5)
-
Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer
Authors (first, second and last of 11)
-
Immune cell infiltration features and related marker genes in lung cancer based on single-cell RNA-seq
Authors (first, second and last of 6)
-
A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment
Authors (first, second and last of 9)
-
Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study
Authors (first, second and last of 13)
-
Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients
Authors (first, second and last of 9)
-
Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
Authors (first, second and last of 15)
-
-
Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma
Authors (first, second and last of 5)
-
